- This event has passed.
NCI Tech Opportunity Webinar: Single Domain Antibodies Targeting SARS-CoV-2 for treating COVID-19
September 28, 2021 @ 11:00 AM – 12:00 PM
Attendees will hear about licensing and co-development opportunities from the NCI’s Dr. Mitchell Ho for a potential therapeutic treatment for COVID-19, “Single Domain Antibodies Targeting SARS-CoV2 for Treating Covid-19.” There are few therapeutics available for COVID-19 patients that directly target the SARS-CoV-2 novel coronavirus. Dr. Ho’s lab isolated three lead nanobodies, 7A3, 1B5, and 2F7, which were found to be highly effective at blocking RBD-ACE2 binding interactions. This nanobody panel has the potential to block the binding of the S-protein to the ACE2 receptor, thereby preventing SARS-CoV-2 virus from binding to and entering host cells to cause COVID-19 infection. This technology is pre-clinical with identified lead compounds. It is patent pending and available for licensing or co-development.